Tricuspid Transcatheter Edge-to-Edge Repair (T-TEER): A Single Approach to a Multiforme Pathology.

PURPOSE OF REVIEW

This review aims to analyze the current state of transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation, emphasizing patient phenotypes enrolled in major trials and registries, and discussing potential pharmacological treatment strategies for this complex pathology.

RECENT FINDINGS

Recent studies have highlighted the significant impact of tricuspid regurgitation on morbidity and mortality in patients with valvular heart disease, heart failure, and pulmonary hypertension. Advances in multimodality imaging have improved phenotyping of TR, while T-TEER trials and registries have demonstrated improvements in TR severity and quality of life. However, mortality outcomes remain neutral. Novel therapies such as SGLT2 inhibitors show promise, particularly in patients with concomitant HFpEF and HFrEF, and ongoing trials are broadening the inclusion criteria to better represent real-world populations. T-TEER represents a promising interventional strategy for managing tricuspid regurgitation, yet challenges persist due to the heterogeneous nature of the disease and differences between trial and real-world populations. Optimizing patient selection and integrating advanced imaging and novel pharmacotherapies may further enhance clinical outcomes and reduce hospitalizations, paving the way for more personalized treatment approaches.